Dow Turns Positive as Value Stocks Get Vaccine Boost

Investing.com

Published Dec 08, 2020 01:24PM ET

Updated Dec 08, 2020 03:06PM ET

By Yasin Ebrahim

Investing.com - The Dow turned positive Tuesday, as the prospect of a vaccine roll out in the U.S. as early as this week eased concerns about the economic threat amid fresh lockdown measures across states to curb the rise in infections.

The Dow Jones Industrial Average rose 0.38%, or 115 points. The S&P 500 was up 0.31%, while the Nasdaq Composite 0.52%.

The Food and Drug Administration said Tuesday that data from the clinical trials of the Pfizer-BioNTech vaccine met its safety standards, stoking hopes the drug could be approved for Emergency Use Authorization in the coming days.

Emergency Use Authorization in the U.S. would follow a similar move in the UK, which got its vaccination program underway earlier Tuesday.

The vaccine news eased investor worries about the economic impact from fresh lockdown measures across states to curb the spread of infections and injected a shot of optimism across value stocks, with energy stocks leading the advance.

Pioneer Natural Resources (NYSE:PXD), Occidental Petroleum (NYSE:OXY), and Marathon Oil (NYSE:MRO) were among the biggest gainers in energy, with the latter up more than 4% as investors bet on a vaccine-fueled uptick in demand.

Industrials were not far behind, up nearly 1%, underpinned by a 8% surge in Equifax (NYSE:EFX) as the consumer credit reporting company received an upgrade from Barclays (LON:BARC) to overweight from underweight.

Boeing (NYSE:BA) fell 0.5% after the aircraft maker said orders for its beleaguered 737 Max, which was involved in two fatal crashes, declined by 63 last month, taking the total cancellations for the year through November to 1,068.

Ahead of key quarterly reports from Broadcom (NASDAQ:AVGO), Adobe (NASDAQ:ADBE) and Costco (NASDAQ:COST) later this week, investors digested mixed earnings from AutoZone and Stich Fix.

AutoZone (NYSE:AZO) reported earnings of $18.61 a share that topped expectations, but revenue of $3.15 billion fell short of estimates, sending its shares down 6%.

Stich Fix, meanwhile, surged 40% after reporting a surprise fiscal first-quarter profit on higher revenue, prompting a slew of analysts on Wall Street to upgrade their estimates on the stock.

RBC lifted its price target on Stitch Fix (NASDAQ:SFIX) to $64 from $50 amid expectations for net additions and revenue growth acceleration, and Ebitda margin expansion in fiscal 2021.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes